Taysha Gene Therapies, Inc. (TSHA) Financials
TSHA Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 470.4 million | 83.2 million |
| March 31, 2026 | 300.4 million | 88.4 million |
| Dec. 31, 2025 | 343.3 million | 96.4 million |
| Sept. 30, 2025 | 316.6 million | 97.6 million |
TSHA Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -40.4 million | 5.8 million |
| March 31, 2026 | -43.9 million | 5.5 million |
| Dec. 31, 2025 | -27.0 million | 3.5 million |
| Sept. 30, 2025 | -24.3 million | 3.3 million |
TSHA Net Income
No data available :(
TSHA Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 455.4 million | 49.3 million | 6.3 million |
| March 31, 2026 | 276.6 million | 17.8 million | 19.6 million |
| Dec. 31, 2025 | 319.8 million | 18.2 million | 20.0 million |
| Sept. 30, 2025 | 297.3 million | 50.9 million | 18.2 million |
TSHA Shares Outstanding
TSHA Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 1000 | 38.6 million | 12.1 million | - |
| March 31, 2026 | 3.0 million | 33.8 million | 9.7 million | - |
| Dec. 31, 2025 | 250000 | 24.7 million | 8.8 million | - |
| Sept. 30, 2025 | 108000 | 25.5 million | 8.3 million | - |
TSHA Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 295000 |
| Dec. 31, 2025 | 5.5 million | 299000 |
| Sept. 30, 2025 | - | 286000 |
TSHA
Price: $3.73
52 week price:
Earnings Per Share: -0.41 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 1.1 million
Market Capitalization: 1.4 billion